Deputy general managers of pharmaceutical companies set off a "wave of departures", and more than 7 "left" in October

【Pharmaceutical Network Industry News】On October 31, a number of pharmaceutical companies announced the resignation
of the company's deputy general manager.
Dafo Pharmaceutical issued an announcement that the company's board of directors received a resignation report submitted by Liu Zhanfeng, deputy general manager in charge of (production) on October 31, 2022, and Liu Zhanfeng resigned from the position of deputy general manager due to personal reasons, effective from October 31
, 2022.
Liu Zhanfeng no longer held other positions
in the company after his resignation.
Fu'an Pharmaceutical announced that Mr.
Xu Peng applied to resign from the position of deputy general manager of the
company due to personal reasons.
After resigning, he will no longer hold other positions
in the company.
As at the date of this announcement, Mr.
Xu Peng does not hold any shares in
the Company.
Celi Medical announced that the board of directors recently received a written resignation report submitted by Mr.
Liu Feng, deputy general manager of the company, and Mr.
Liu Feng resigned from the position of
deputy general manager of the company for personal reasons.
After Mr.
Liu Feng resigned, he no longer held any position
in the company.
Rejing Bio also issued an announcement on the evening of the 31st that Mr.
Sun Haifeng applied to resign from the position of deputy general manager due to personal reasons, and no longer held any position
in the company after his resignation.
As of the date of disclosure of this announcement, Mr.
Sun Haifeng does not directly hold shares in the Company, but indirectly holds about 120,000 shares of the Company through Beijing Tongcheng Rejing Investment Management Partnership, accounting for 0.
1334%
of the total share capital of the Company.
At present, in the context of intensified changes in the pharmaceutical market, senior executives change frequently, and the deputy general managers of pharmaceutical companies seem to have set off a "wave of departure"
.
In addition to the above-mentioned deputy general managers of pharmaceutical companies, a number of deputy general managers of pharmaceutical companies have announced their "departure"
in the past month.
FOR EXAMPLE, ON OCTOBER 25, SHANGHAI CATSUNTECH PHARMACEUTICAL ANNOUNCED THAT THE BOARD OF DIRECTORS RECENTLY RECEIVED THE RESIGNATION REPORT
OF MR.
MAOJIAN GU, DEPUTY GENERAL MANAGER OF THE COMPANY.
DUE TO HIS AGE, MR.
MAOJIAN GU APPLIED TO RESIGN AS
DEPUTY GENERAL MANAGER OF THE COMPANY.
AFTER RESIGNING AS DEPUTY GENERAL MANAGER, MR.
MAOJIAN GU WILL CONTINUE TO SERVE AS A DIRECTOR AND OTHER POSITIONS
IN THE COMPANY.
On October 19, Harbin Pharmaceutical issued an announcement that Mr.
Lu Chuanyou resigned from the position of
deputy general manager of the company due to retirement reasons.
As of the disclosure date of this announcement, Mr.
Lu Chuanyou does not hold shares in the company, and there are no commitments that should be fulfilled but not fulfilled
.
On October 10, Hengrui Pharmaceutical announced that Tao Weikang, deputy general manager of the company, resigned due to personal reasons, and after his resignation, Tao Weikang will no longer hold any position in the company, and the relevant work he is responsible for has been handed over
.
Tao Weikang has been engaged in new drug research and development for more than ten years at Merck Pharmaceutical Company in the United States, serving as a senior researcher and department head, and presided over the research and development and project management
of a number of new anti-cancer drugs.
He has served as the deputy general manager of Shanghai Hengrui Pharmaceutical Co.
, Ltd.
and the CEO of the R&D center since 2014, and has been the deputy general manager
of the company since July 2015.
On the same day, Hengrui Pharmaceutical appointed He Feng as the deputy general manager of Hengrui Pharmaceutical, who will undertake the new drug research and development and R&D management of
Shanghai Hengrui R&D Center.
It is reported that He Feng has worked at Bristol-Myers Squibb, Novartis and AbbVie, engaged in the research and development of innovative drugs in the field of
viruses, cancer, kidney diseases and other diseases.
It is worth mentioning that Hengrui Pharmaceutical has resigned three deputy general managers since the beginning of the year, in addition to Tao Weikang, on April 12, Zou Jianjun applied to resign from the position of deputy general manager of the company for personal reasons, and on February 25, Zhang Yuehong applied to resign from the position of deputy general manager of the company for personal reasons
.
Judging from the reasons for the departure of the above-mentioned deputy general managers of pharmaceutical companies, most of them are mainly personal reasons, followed by retirement reasons and age reasons
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice
to anyone.